# Alloy Therapeutics

> Alloy Therapeutics is a VC fund backing Biotechnology and Therapeutics. See 10 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Lexington, United States
- Total investments: 10
- Last investment: Mar 2025
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/alloy-therapeutics-inc/
- X (Twitter): https://twitter.com/alloytx?lang=en
- Website: https://www.alloytx.com/

Alloy Therapeutics is a VC fund in Lexington focused on Biotechnology and Therapeutics. Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Lexington, Massachusetts.

## Contacts

5 contacts available for Alloy Therapeutics. Shizune tracks 3 team members at Alloy Therapeutics. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/alloy-therapeutics?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 40% |
| Therapeutics | 2 | 20% |
| Health Care | 1 | 10% |
| Life Science | 1 | 10% |
| Service Industry | 1 | 10% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 30% |
| Seed | 2 | 20% |
| Funding Round | 2 | 20% |
| Corporate Round | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Joshua Brandt | Associate General Counsel | 0 | https://shizune.co/investors/profile/joshua-brandt |
| Richard Shimkets | SVP Genetics and New Technologies | 0 | https://shizune.co/investors/profile/richard-shimkets |
| Errik Anderson | Founder, Chairman and CEO | 7 | https://shizune.co/investors/profile/errik-anderson |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Wheeler Bio | Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $35M | Series A | Mar 20, 2025 |  |
| Wheeler Bio | Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $31M | Series A | Oct 04, 2022 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M |  | Jun 02, 2022 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. | $21M | Series A | Jun 02, 2022 |  |
| Tegmine Therapeutics | Tegmine Therapeutics is private, seed-stage biotech that develops antibody-based therapeutics targeting proteins and their disease-related glycan modifications. |  | Corporate Round | Apr 06, 2022 |  |
| Mytide Therapeutics | Mytide is committed to providing peptides to serve a diverse array of applications. They intend to work closely with partners to overcome challenges in synthesizing and purifying particular classes of peptides of interest, identify useful peptide modifications, and design and construct peptide libraries. They provide initial partners access totheir cloud platform for immediate ordering, properties calculator, order tracking, and interactive data display. | $7M | Series A | Mar 08, 2022 |  |
| Wheeler Bio | Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. | $14M | Seed | Jan 04, 2022 |  |
| Wheeler Bio | Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. |  |  | Jul 21, 2021 |  |
| Wheeler Bio | Wheeler Bio is a new biomanufacturing company designed to accelerate the translation of therapeutic innovation into clinical impact. Through parallel integration with pre-clinical discovery, Wheeler is democratizing access to comprehensive discovery-to-IND programs with its rapid, high-quality biomanufacturing and portable CMC platform. |  | Seed | Jul 21, 2021 |  |
| Vernal Biosciences | Vernal Biosciences is an mRNA manufacturing company that provides high purity mRNA, from concept to clinical trials, on a transactional basis. |  | Seed | Jul 12, 2021 |  |

10 of 10 investments shown.

## Co-investors
- [Echo Investment Capital](https://shizune.co/investors/profile/echo-investment-capital) — VC Fund, 5 deals together
- [Charles River Laboratories International](https://shizune.co/investors/profile/charles-river-laboratories-international) — VC Fund, 3 deals together
- [Atum](https://shizune.co/investors/profile/atum-6aa8) — VC Fund, 2 deals together
- [Dynamk Capital](https://shizune.co/investors/profile/dynamk-capital) — VC Fund, 2 deals together
- [Ampersand Capital Partners](https://shizune.co/investors/profile/ampersand-ventures) — VC Fund, 1 deal together
- [Floating Point Group](https://shizune.co/investors/profile/floating-point-group) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Alloy Therapeutics invest in?

Alloy Therapeutics invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Alloy Therapeutics?

Public channels for Alloy Therapeutics include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Alloy Therapeutics?

The team at Alloy Therapeutics includes Joshua Brandt (Associate General Counsel), Richard Shimkets (SVP Genetics and New Technologies) and Errik Anderson (Founder, Chairman and CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co